Charlotte Billiet

Charlotte Billiet

Auto-generated profile, based on publicly available information

Charlotte Billiet

Department of Radiation Oncology, University of Antwerp, Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
CBCharlotte Billiet
Charlotte Billiet
HDHerbert Decaluwé
Herbert Decaluwé
SPStephanie Peeters
Stephanie Peeters
JVJohan Vansteenkiste
Johan Vansteenkiste
CDChristophe Dooms
Christophe Dooms
DRDirk De Ruysscher
Dirk De Ruysscher

6 April 2024 in Cancer
Verified
Journal Article
Open access
MGMatthias Guckenberger
Matthias Guckenberger
CBCharlotte Billiet
Charlotte Billiet
DSDaniel Schnell
Daniel Schnell
CFCiro Franzese
Ciro Franzese
Mateusz Jacek SpałekMateusz Jacek Spałek
Mateusz Jacek Spałek
IMIndira Madani
Indira Madani
Background: The purpose of this randomised study was to determine whether dose‐intensified stereotactic body radiotherapy (SBRT) for painful vertebral metastases results in increased rates of pain improvement compared with conventional external beam radiotherapy (cEBRT) (control) 6 months after treatment.Methods: This randomized, controlled phase 3 trial was conducted between November 2016 and January 2023, when it was stopped early. Patients were eligible if they were aged 18 years or older; had one or two painful, stable, or potentially unstable vertebral metastases; and had a life expectancy of 1 year or longer according to the investigator's estimates. Patients received 48.5 grays (Gy) in 10 fractions (with epidural involvement) or 40 Gy in five fractions (without epidural involvement) in the SBRT group and 30 Gy in 10 fractions or 20 Gy in five fractions in the cEBRT group, respectively. The primary end point was an improvement in the pain score at the treated site by at least 2 points (on a visual analog scale from 0 to 10 points) at 6‐month follow‐up. Data were analyzed on an intention‐to‐treat and per‐protocol basis.Results: Of 214 patients who were screened for eligibility, 63 were randomized 1:1 between SBRT (33 patients with 36 metastases) and cEBRT (30 patients with 31 metastases). The median age of all patients was 66 years, and 40 patients were men (63.5%). In the intention‐to‐treat analysis, the 6‐month proportion of patients who had metastases with pain reduction by 2 or more points was significantly higher in the SBRT group versus the control group (69.4% vs. 41.9%, respectively; two‐sided p = .02). Changes in opioid medication intake relative to baseline were nonsignificant between the groups. No differences were observed in vertebral compression fracture or adverse event rates between the groups.Conclusions: Dose‐intensified SBRT improved pain score more effectively than cEBRT at 6 months.

1 September 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
CBCharlotte Billiet
Charlotte Billiet
DRDirk De Ruysscher
Dirk De Ruysscher
SPStéphanie Peeters
Stéphanie Peeters
HDHerbert Decaluwé
Herbert Decaluwé
JVJohan Vansteenkiste
Johan Vansteenkiste
JMJeroen Mebis
Jeroen Mebis

1 November 2016 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
CBCharlotte Billiet
Charlotte Billiet
SPStéphanie Peeters
Stéphanie Peeters
HDHerbert Decaluwé
Herbert Decaluwé
JVJohan Vansteenkiste
Johan Vansteenkiste
CDChristophe Dooms
Christophe Dooms
Dirk De RuysscherDirk De Ruysscher
Dirk De Ruysscher

1 December 2016 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
CBCharlotte Billiet
Charlotte Billiet
SPStéphanie Peeters
Stéphanie Peeters
HDHerbert Decaluwé
Herbert Decaluwé
JVJohan Vansteenkiste
Johan Vansteenkiste
JMJeroen Mebis
Jeroen Mebis
DRDirk De Ruysscher
Dirk De Ruysscher

15 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MGMaria Ghita
Maria Ghita
CBCharlotte Billiet
Charlotte Billiet
Dana CopotDana Copot
Dana Copot
DVDirk Verellen
Dirk Verellen
Clara IonescuClara Ionescu
Clara Ionescu
Individual curves for tumor growth can be expressed as mathematical models. Herein we exploited a pharmacokinetic-pharmacodynamic (PKPD) model to accurately predict the lung growth curves when using data from a clinical study. Our analysis included 19 patients with non-small cell lung cancer treated with specific hypofractionated regimens, defined as stereotactic body radiation therapy (SBRT). The results exhibited the utility of the PKPD model for testing growth hypotheses of the lung tumor against clinical data. The model fitted the observed progression behavior of the lung tumors expressed by measuring the tumor volume of the patients before and after treatment from CT screening. The changes in dynamics were best captured by the parameter identified as the patients’ response to treatment. Median follow-up times for the tumor volume after SBRT were 126 days. These results have proven the use of mathematical modeling in preclinical anticancer investigations as a potential prognostic tool.